Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Alzheimer's and Parkinson's disease are the two most common neurodegenerative disorders. They develop after a progressive death of many neurons in the brain. Although therapies are available to treat the signs and symptoms of both diseases, the progression of neuronal death remains relentless, and it has proved difficult to slow or stop. Hence, there is a need to develop neuroprotective or disease-modifying treatments that stabilize this degeneration. Red to infrared light therapy (λ = 600-1070 nm), and in particular light in the near infrared (NIr) range, is emerging as a safe and effective therapy that is capable of arresting neuronal death. Previous studies have used NIr to treat tissue stressed by hypoxia, toxic insult, genetic mutation and mitochondrial dysfunction with much success. Here we propose NIr therapy as a neuroprotective or disease-modifying treatment for Alzheimer's and Parkinson's patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease
Benabid, A. L., Chabardes, S., Mitrofanis, J., & Pollak, P. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70291-6 · Cited by 1,285
Self-citationThe Cell Non-Autonomous Nature of Electron Transport Chain-Mediated Longevity
Durieux, J., Wolff, S., & Dillin, A. (2011) · Cell · doi:10.1016/j.cell.2010.12.016 · Cited by 1,059 · cited 2×
“For example, NIr has been reported beneficial in animal models of retinal disease (Eells et al., 2004; Natoli et al., 2010, 2013; Albarracin et al., 2013; Begum et al., 2013; Gkotsi et al., 2014), traumatic brain (Ando et al., 2011; Oron et al., 2012; Quirk et al., 2012a; Xuan et al., 2013, 2014,…”
BackgroundSpreading of pathology in neurodegenerative diseases: a focus on human studies
Brettschneider, J., Tredici, K. D., Lee, V. M.-Y., & Trojanowski, J. Q. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3887 · Cited by 790
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768 · cited 4×
“…the signs and symptoms associated with each disorder worsen, making many routine day-day activities increasingly more difficult for patients (Tierney et al., 2013; Schapira et al., 2014; Brettschneider et al., 2015; Coppedè and Migliore, 2015; Goedert, 2015; Herrup, 2015; Nelson and Tabet, 2015).”
BackgroundInfluentialA “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease
Swerdlow, R. H., & Khan, S. M. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.12.045 · Cited by 758 · cited 2×
“This process would lead to an increase in toxic reactive oxygen species, generating oxidative stress and subsequent neuronal death, as observed in Alzheimer’s disease (Swerdlow and Khan, 2004; Chaturvedi and Beal, 2008; Gonzalez-Lima et al., 2014; Coppedè andMigliore, 2015).”
BackgroundCharacterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease
Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., Prada, C., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.017 · Cited by 744 · cited 1×
“The majority of the transgenic animal models of the disease are, in fact, based on mutations of these proteins (e.g., Garcia-Alloza et al., 2006; van Eersel et al., 2010).”
BackgroundBlood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
Mitochondrial Approaches for Neuroprotection
Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294 · cited 2×
“This process would lead to an increase in toxic reactive oxygen species, generating oxidative stress and subsequent neuronal death, as observed in Alzheimer’s disease (Swerdlow and Khan, 2004; Chaturvedi and Beal, 2008; Gonzalez-Lima et al., 2014; Coppedè andMigliore, 2015).”
Backgroundvan Eersel, J., Ke, Y. D., Liu, X., Delerue, F., Kril, J. J., Götz, J., & Ittner, L. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009038107 · Cited by 284
Improving executive function using transcranial infrared laser stimulation
Blanco, N. J., Maddox, W. T., & Gonzalez‐Lima, F. (2017) · Journal of Neuropsychology · doi:10.1111/jnp.12074 · Cited by 179 · cited 6×
“In the sections that follow, the different patterns of neurodegeneration, clinical syndromes and current treatments for each disease will be considered separately.”
BackgroundInfluentialPericapillary Haem-Rich Deposits: Evidence for Microhaemorrhages in Aging Human Cerebral Cortex
Cullen, K. M., Kócsi, Z., & Stone, J. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600155 · Cited by 137 · cited 2×
“In essence, this hypothesis proposes that the breakdown of cerebral capillaries as a consequence of aging results in microhemorrhages that in turn lead to the formation of plaques, tangles, and subsequent neuronal death (Cullen et al., 2005, 2006; Stone, 2008).”
BackgroundSelf-citationNear‐infrared light is neuroprotective in a monkey model of Parkinson disease
Darlot, F., Moro, C., El Massri, N., Chabrol, C., Johnstone, D. M., Reinhart, F., Agay, D., Torres, N., Bekha, D., Auboiroux, V., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24542 · Cited by 114
Self-citation
Cited by
Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation
Hamblin, M. R. (2018) · Photochemistry and Photobiology · doi:10.1111/php.12864 · Cited by 820
Shining light on the head: Photobiomodulation for brain disorders
Hamblin, M. R. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.09.002 · Cited by 627
Biological effects and medical applications of infrared radiation
Tsai, S.-R., & Hamblin, M. R. (2017) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2017.04.014 · Cited by 477
Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease
Church, F. C. (2021) · Biomolecules · doi:10.3390/biom11040612 · Cited by 290
Wang, N., Xue, Y., Wang, T., Qiu, F., Li, C., Wang, Z., Jiang, J., Lu, Y., Shao, Y., Bai, Z., et al. (2025) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-025-01679-9 · Cited by 4
“Additionally, cold light has been shown to exert neuroprotective effects by reducing oxidative stress—primarily through its action on mitochondrial function—which helps preserve neuronal integrity and function [57].”
Metadata
- Authors
- Johnstone, D. M., Moro, C., Stone, J., Benabid, A.-L., & Mitrofanis, J.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2016-01-11
- Volume
- 9
- Pages
- 500-500
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2264781189
- Cited by
- 168
- References
- 14
- FWCI
- 13.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.